[1] [1]Angehrn, W. (2001) Chronic Ischemic Heart Disease. Forum Médical Suisse, 8, 1187-1191.
[2] Ferrario, M., Cesana, G. and Vanuzzo, D. (2001) Surveillance of Ischaemic Heart Disease: Results from the Italian Monico Population. International Journal of Epidemiology, 30, 23-29.
https://doi.org/10.1093/ije/30.suppl_1.S23
[3] Murray, C.J. and Lopez, A.D. (1997) Alternative Projections of Mortality and Disability by Cause 1990-2020: Global Burden of Disease Study. The Lancet, 349, 1498-1504.
https://doi.org/10.1016/S0140-6736(96)07492-2
[4] Ladenheim, M.L., Pollock, B.H., Rozanski, A., Berman, D.S., Stanilof, H.M., Forrester, J.S., et al. (1986) Extent and Severity of Myocardial Hypoperfusion as Predictors of Prognosis in Patients with Suspect Coronary Artery Disease. Journal of the American College of Cardiology, 7, 464-471.
https://doi.org/10.1016/S0735-1097(86)80454-5
[5] Northridge, D.B., Grand, S., Henderson, E., Ray, S., Mcmurray, J. and Dargie, H.J. (1990) A Novel Exercise Protocol Suitable for Use on a Treadmill or a Bicycle Ergometer. British Heart Journal, 64, 313-316.
https://doi.org/10.1136/hrt.64.5.313
[6] Diamond, G.A. and Forrester, J.S. (1979) Analysis of Probability in the Clinical Diagnosis of Coronary Artery Disease. The New England Journal of Medicine, 300, 1350-1358.
https://doi.org/10.1056/NEJM197906143002402
[7] Sanmarco, M.E., Pontius, S. and Selvester, R.H. (1980) Abnormal Blood Pressure Response and Marked Ischemic St-Segment Depression as Predictors of Severe Coronary Artery Disease. Circulation, 61, 572-578.
https://doi.org/10.1161/01.CIR.61.3.572
[8] Depuey, E.G. (1994) How to Detect and Avoid Myocardial Perfusion SPECT Artifacts. The Journal of Nuclear Medicine, 35, 699-702.
[9] Dunet, V., Costo, S., Sabatier, R., Grollier, G., Bouvard, G. and Agostini, D. (2010) Feasibility and Diagnostic Accuracy of a Myocardial Scintigraphy Protocol Synchronized with E.C.G in Two Hours: The Myofaste Study. Nuclear Medicine, 34, 211-218.
[10] Jain, D., Wackers, F.J., Mattera, J., Mc Mahon, M., Sinusas, A.J. and Zaret, B.L. (1993) Biokinetics of Technetium-Tétrofosmine: Myocardial Perfusion Imaging Agent: Implications for a One-Day Imaging Protocol. The Journal of Nuclear Medicine, 34, 1254-1259.
[11] Flamen, P., Bossuyt, A. and Franken, P.R. (1995) Technetium-99m-Tetrofosmin in Dipyridamole-Myocardial Stress SPECT Imaging: Intraindividual Comparison with Technetium-99m-Sestamibi. The Journal of Nuclear Medicine, 36, 2009-2015.
[12] Vanzetto, G., Machecourt, J. and Fagret, D. (2000) Myocardial Perfusion Tomoscintigraphy (Mpts) and Prognostic Evaluation of Coronary Artery Disease. Review of the Acomen, 6, 114-121.
[13] Abdenbi, K. (2002) Smoking Cessation in the Coronary. Annales de Cardiologie et d'Angéiologie, 51, 357-366.
https://doi.org/10.1016/S0003-3928(02)00148-8
[14] Worker, M.J., Bernard, M., Hitzel, A., Vera, P. and Manrique, A. (2009) Evaluation of Myocardial Sideration Post-Exertion Immediately by Tomoscintigraphy with 99mtc Coupled to the ECG. Nuclear Medicine, 33, 331-337.
[15] Manrique, A. and Marie, P.Y. (2003) Recommendations for the Performance and Interpretation of Myocardial Perfusion Tomoscintigraphy. Archives des Maladies du Coeur et des Vaisseaux, 96, 695-711.
[16] Calizzano, A. (2007) Current Position and Future Prospects of Myocardial Perfusion Scintigraphy. Nuclear Medicine, 31, 604-609.
[17] Levy, M. (2006) Myocardial Scintigraphy and Prognosis in Coronary Disease. MT Cardiologists, 2, 223-234.